Telomir Pharmaceuticals (TELO) Other Accumulated Expenses (2023 - 2026)

Telomir Pharmaceuticals has reported Other Accumulated Expenses for 3 years, with the latest figure at $318234.0 in Q4 2025.

• Quarterly Other Accumulated Expenses rose 240.6% year-over-year to $318234.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $318234.0 (up 240.6% YoY) and the FY2025 annual result came in at $318234.0, up 240.6% from the prior year.
• Other Accumulated Expenses climbed to $318234.0 in Q4 2025 per TELO's latest filing, from $100000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $527377.0 in Q4 2023 and troughed at $93432.0 in Q4 2024.
• A 3-year average of $204317.8 and a median of $96716.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses sank 82.28% in 2024, then jumped 240.6% in 2025.
• Over 3 years, Other Accumulated Expenses stood at $527377.0 in 2023, then tumbled by 82.28% to $93432.0 in 2024, then surged by 240.6% to $318234.0 in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $318234.0, $100000.0, and $93432.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.